EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation

Jayita Goswami, Prithviraj Uttarasili, Lakshay Garg, Prasasvi Kaval Reddy, Abhishek Chowdhury, Subhrodeep Saha, Jayanta Chatterjee, Anand Srivastava iD, Kumaravel Somasundaram iD

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 05.06.2026. Verfasst von Jayita Goswami und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSIR for the graduate fellowship, DST FIST, DBT-IISc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) remains a deadly brain tumor. Activation of the wild-type calcitonin receptor (CTR) by salmon calcitonin (sCT) suppresses glioma growth, whereas patient-derived CTR mutants drive tumor progression and correlate with poor survival. This study delineates the mechanisms underlying sCT-mediated tumor suppression and reveals structural defects in oncogenic CTR variants.

Methods

Proteome analysis of sCT-treated glioma cells was done to dissect the altered signaling. Multiple experimental approaches were used to elucidate the signaling behind CTR-dependent Hippo pathway activation. The therapeutic efficacy of sCT on the growth of human/murine glioma stem-like cells (GSC)-initiated tumors in an orthotopic mouse glioma model was assessed. Extensive microsecond-scale all-atom molecular dynamics simulations were performed to elucidate the structural impairments in CTR mutants. Results sCT treatment activated Hippo signaling as demonstrated by enhanced phosphorylation and subsequent degradation of YAP/TAZ and suppressed glioma growth through cAMP/PKA/LATS1 signaling in vitro. However, GSCs expressing a phosphorylation-resistant YAP mutant were refractory to sCT treatment in vitro. Both human and murine GSCs exhibited elevated CTR expression, and intranasal administration of sCT effectively inhibited the growth of GSC-initiated tumors. Furthermore, molecular dynamics simulations revealed structural perturbations in CTR interactions with either CT or the Gα subunit.

Conclusions

We establish that activation of the sCT-CTR axis suppresses glioma growth by inhibiting YAP/TAZ through Hippo pathway activation. We further delineate the structural aberrations responsible for the functional loss in patient-derived CTR mutants. Thus, we present compelling evidence supporting the therapeutic repurposing of calcitonin for GBM treatment.

Schlagwörter

Stichwörter der Autor:innen

G protein-coupled receptorcalcitonin receptorglioblastomahippo signalingsalmon calcitonin

Autor:innen und Institutionen

  • Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
  • Molecular Biophysics Unit, Indian Institute of Science, Bangalore, India.

ORCID-Profile: Anand Srivastava, Kumaravel Somasundaram

Förderung

  • CSIR for the graduate fellowship
  • DST FIST
  • DBT-IISc
  • National Supercomputing Mission grants
  • Department of Science and Technology
  • DBT-Wellcome Trust India Alliance
  • DBT National Network Project
  • Science and Engineering Board

Zitieren

APA

Goswami, J., Uttarasili, P., Garg, L., Kaval Reddy, P., Chowdhury, A., Saha, S., Chatterjee, J., Srivastava, A., & Somasundaram, K. (2026). Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag152

Vancouver

Goswami J, Uttarasili P, Garg L, Kaval Reddy P, Chowdhury A, Saha S, et al. Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag152

BibTeX
@article{Goswami2026,
  author = {Goswami, Jayita and Uttarasili, Prithviraj and Garg, Lakshay and Kaval Reddy, Prasasvi and Chowdhury, Abhishek and Saha, Subhrodeep and Chatterjee, Jayanta and Srivastava, Anand and Somasundaram, Kumaravel},
  title = {Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag152}
}
Kostenlos starten →